All In Biotech

Drug Trial Radar · NCT07723482

ML-016 in Advanced Cancer With Lung and/or Liver Involvement

Phase 1/2 Study of ML-016 in Participants With Advanced Cancer With Lung and/or Liver Involvement

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Oct 2027

Study completion Oct 2030

Sponsor

Lead sponsor
BrYet US, Inc.Industry
Sponsor type
Industry
Collaborators
Southern Star Research
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).

Conditions

  • Advanced Solid Tumor With Lung and/or Liver Involvement

Interventions

  • ML-016Drug

    a pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) during the DLT assessment periodTime frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)
  2. Frequency and severity of adverse events (AEs) and serious AEs (SAEs)Time frame: From first dose of study drug through 30 days following the last dose of study drug
  3. Maximum tolerated dose (MTD) and doses recommended for expansionTime frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)
  4. Vital Signs: Blood PressureTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
  5. Vital Signs: Heart RateTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
  6. Electrocardiograms (ECGs): QT IntervalTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
  7. Echocardiograms (ECHO): LVEFTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Southside Cancer Care Centre

    Miranda, New South Wales, Australia · Recruiting

  • Illawarra Cancer Care Center, Wollongong Hospital

    Wollongong, New South Wales, Australia · Not yet recruiting

  • Sunshine Coast Haematology and Oncology Clinic

    Buderim, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.